ADH5 and cystic fibrosis: Currently, several reversible GSNOR selective inhibitors (GSNORi) have been developed, and among them, N6022 has been tested in Phase I and II trials for asthma and cystic fibrosis and proven to meet the safety standard for human use (Colagiovanni et al., 2012).